TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
|Articles|August 6, 2009
For Easier Pap Smears, Use a Condom
Performing Papanicolaou tests in obese patients can be difficult
Advertisement
Performing Papanicolaou tests in obese patients can be difficult: during the speculum examination, the sidewalls of the vagina tend to occlude your view of the cervix. I have found that cutting off the tip of a condom and rolling it over the speculum provides substantial resistance to the sidewalls, thereby improving visualization of the cervix.
Adam J. Breinig, DO
Charleston, WVa
Would you find this Pointer helpful in your practice?
Advertisement
Related to this article
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
A new scientific statement calls for a shift in obesity management and treatment to focus on overall health improvements rather than just weight loss alone.
Advertisement
Advertisement
Trending on Patient Care Online
1
Menopause Hormone Therapy Linked to Greater Weight Loss With Semaglutide in Real-World Study
2
Menopause Diagnoses Documented in Just 7.8% of Midlife Women's Outpatient Visits, Study Finds
3
JoAnn Pinkerton, MD, on Counseling Patients Starting Elinzanetant for VMS
4
Fezolinetant May Improve Depression, Anxiety Symptoms in Women With Menopausal VMS
5